• Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines. PDF file to download
    Ann Transl Med. 2016 Jul;4(14):266
    Menez-Jamet J, Gallou C, Rougeot A, Kosmatopoulos K.
  • A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients. PDF file to download
    Oncotarget. 2016 Sep 13;7(37):59417-59428
    Gallou C, Rougeot A, Graff-Dubois S, Kosmatopoulos K, Menez-Jamet J.
  • A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide.
    Lung Cancer. 2014 Oct;86(1):59-66
    Kotsakis A, Papadimitraki E, Vetsika EK, Aggouraki D, Dermitzaki EK, Hatzidaki D, Kentepozidis N, Mavroudis D, Georgoulias V.
  • A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine, as maintenance treatment in advanced non-small cell lung cancer : treatment rationale and protocol dynamics, PDF file to download
    Clin. Lung Cancer, 2013, 14, 461-5

    Georgoulias V., Douillard JY., Khayat D., Manegold C., Rossel R., Rossi A., Menez-Jamet J., Iché M., Kosmatopoulos K., Gridelli C 
  • Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase I study. PDF file to download
    Ann. Oncol., 2012, 23: 442-9

    Kotsakis A., Vetsika E.K., Christou S., Hatzidaki D., Vardakis N., Aggouraki D., Konsolakis G., Georgoulias V., Christophylakis C., Cordopatis P., Kosmatopoulos K., Mavroudis D.
  •  Immunological response in cancer patients after vaccination with the therapeutic telomerase specific v accine Vx-001. PDF file to download
    Cancer Immunol. Immunother., 2012, 61: 157-68,

    Vetsika E.K, Konsolakis G., Aggouraki D., Kotsakis A., Papadimitraki E., Christou S., Menez-Jamet J., Kosmatopoulos K., Georgoulias V., Mavroudis D.
  •  Development of optimized cryptic peptides in immunotherapy. PDF file to download
    iDrug, 2009, 12, 92-102,
    Menez-Jamet J and Kosmatopoulos K
  • Improving Tumour Immunity. PDF file to download
    European Biotech Review, 2007 Summer, 56-58,
    Abastado JP and Kosmatopoulos K
  • Vaccination of Patients With Advanced Non–Small-Cell Lung Cancer With an Optimized Cryptic Human Telomerase Reverse Transcriptase Peptide. PDF file to download
    Journal of Clinical Oncology, 2007 July, 25 (19), 2729-34;
    Bolonaki I, Kotsakis A, Papadimitraki E, Aggouraki, D Konsolakis G, Vagia A, Christophylakis C, Nikoloudi I, Magganas E, Galanis A, Cordopatis P, Kosmatopoulos K, Georgoulias V, and Mavroudis D
  • A Polyepitope DNA Vaccine Targeted to Her-2/ErbB-2 Elicits a Broad Range of Human and Murine CTL Effectors to Protect against Tumor Challenge. PDF file to download
    Cancer Res., 2007 July 15, 67 (14), 7028-36,
    Scardino A, Alimandi M, Correale P, Smith SG, Bei R, Firat H, Grazia Cusi M,  Faure O, Graf-Dubois S, Cencioni G, Marrocco J, Chouaib S, Lemonnier FA,  Jackson AM and Kosmatopoulos K
  • STEAP, a prostate tumor antigen, is a target of human CD8(+) T cells.
    Cancer Immunol Immunother. 2006 Dec;55(12):1515-23,
    Alves PM, Faure O, Graff-Dubois S, Cornet S, Bolonakis I, Gross DA, Miconnet I, Chouaib S, Fizazi K, Soria JC, Lemonnier FA, Kosmatopoulos K.
  • A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies. PDF file to download
    Oncology. 2006;70(4):306-14., 2006 Oct 12,
    Mavroudis D, Bolonakis I, Cornet S, Myllaki G, Kanellou P, Kotsakis A, Galanis A, Nikoloudi I, Spyropoulou M, Menez J, Miconnet I, Niniraki M, Cordopatis P, Kosmatopoulos K, Georgoulias V
  • Optimal organization of a polypeptide-based candidate cancer vaccine composed of cryptic tumor peptides with enhanced immunogenicity. PDF file to download
    Vaccine. 2006 Mar 15;24(12):2102-9,
    Cornet S, Miconnet I, Menez J, Lemonnier F, Kosmatopoulos K.  
  • CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope. PDF file to download
    Vaccine. 2006 Mar 10;24(11):1880-8,
    Cornet S, Menez-Jamet J, Lemonnier F, Kosmatopoulos K, Miconnet I.
  • pH-triggered microparticles for peptide vaccination. PDF file to download
    J Immunol. 2004 Aug 15;173(4):2578-85,
    Haining WN, Anderson DG, Little SR, von Bergwelt-Baildon MS, Cardoso AA, Alves P, Kosmatopoulos K, Nadler LM, Langer R, Kohane DS.
  • High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. PDF file to download
    J Clin Invest. 2004 Feb;113(3):425-33.
    Gross DA,  Graff-Dubois S, Opolon P, Cornet, S Alves P, Faure O, Guillaume P, Chouaib S, Lemonnier, FA, Miconnet I, Vonderheide RH, and Kosmatopoulos K.
  • EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. PDF file to download
    Cancer Res. 2003 Dec 1;63(23):8476-80.
    Alves PM, Faure O, Graff-Dubois S, Gross DA, Cornet S, Chouaib S, Miconnet I, Lemonnier FA, Kosmatopoulos K.
  • Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. PDF file to download
    J Immunol. 2002 Jul 1;169(1):575-80.
    Graff-Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, Lemonnier FA, Kosmatopoulos K.
  • HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. PDF file to download
    J Immunol. 2002 Jun 1;168(11):5900-6.
    Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, Vonderheide RH, Cardoso AA, Kosmatopoulos K.
  • Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. PDF file to download
    Eur J Immunol. 2001 Nov;31(11):3261-70.
    Scardino A, Alves P, Gross DA, Tourdot S, Graff-Dubois S, Angevin E, Firat H, Chouaib S, Lemonnier F, Nadler LM, Cardoso AA, Kosmatopoulos K.
  • A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes. PDF file to download
    Eur J Immunol. 2000 Dec;30(12):3411-21.
    Tourdot S, Scardino A, Saloustrou E, Gross DA, Pascolo S, Cordopatis P, Lemonnier FA, Kosmatopoulos K.